RESEARCH DOSSIER
Stimulant Use Disorders: Cocaine, Methamphetamine, and Treatment
Abstract. Stimulant use disorders are heterogeneous conditions in which psychoactive stimulant exposure, learned reinforcement, altered motivational regulation, contextual opportunities, and clinically significant impairment develop into recurrent patterns of problematic use. This fundamental monograph examines cocaine and methamphetamine through diagnostic frameworks, historical research, pharmacology, reward learning, cue reactivity, intoxication and withdrawal, psychosis and cardiovascular morbidity, longitudinal course, treatment outcomes, and implementation science. Its method is a critical narrative synthesis of original laboratory and clinical studies, randomized behavioral and pharmacological trials, peer-reviewed systematic reviews, the World Health Organization's ICD-11 framework, and the 2024 ASAM/AAAP clinical guideline. The strongest convergent evidence supports contingency management as a central psychosocial treatment, frequently alongside cognitive behavioral treatment and community reinforcement. Candidate medications have yielded selective, generally modest and population-dependent findings, including the naltrexone–bupropion trial in methamphetamine use disorder. Fundamental unresolved problems include causal attribution of persistent cognitive and psychiatric effects, treatment durability, equitable access to effective behavioral care, comorbidity, polydrug exposure, and generalization beyond specialized research settings. The clinical discussion describes evidence and professional recommendations; it does not constitute individual medical treatment instructions.
Keywords: stimulant use disorder; cocaine use disorder; methamphetamine use disorder; addiction psychology; dopamine; reinforcement learning; incentive salience; craving; stimulant intoxication; stimulant withdrawal; contingency management; community reinforcement approach; cognitive behavioral therapy; Matrix Model; pharmacotherapy; naltrexone; bupropion; mirtazapine; substance-induced psychosis; cardiovascular complications; toxicology; recovery; implementation science.
Scientific Overview: The Research Object
Stimulant use disorder is a clinically significant pattern of stimulant use associated with impairment, impaired control, functional harm, and persistence despite consequential problems. Cocaine and methamphetamine are essential comparison cases because both elevate catecholaminergic signaling and can generate powerful reinforcement, yet their pharmacological modes of action, durations, patterns of administration, social settings, and clinical complication profiles differ. The word stimulant encompasses prescribed medications and other substances whose use, therapeutic context, and behavioral consequences require careful differentiation. Therapeutic exposure to a prescribed stimulant does not, by itself, establish a stimulant use disorder. Nor does any single episode of illicit use identify a disorder without the relevant clinical syndrome.
The scientific question is how a drug-related sequence of experiences and decisions acquires such motivational priority that opportunities for non-drug reinforcement, health protection, responsibilities, and relationships become progressively reorganized around use. Its analysis requires multiple explanatory levels: molecular and neural pharmacology; associative learning and decision processes; individual vulnerability and psychiatric comorbidity; cultural, economic, and interpersonal environments; and treatment systems capable of altering the contingencies sustaining behavior. These levels affect one another while remaining empirically distinguishable.
The monograph asks how cocaine and methamphetamine influence reward-related signaling; what features of exposure become diagnostically meaningful; which longitudinal factors predict persistence, recurrence, or remission; why acute intoxication, withdrawal, and stimulant-associated psychosis require separate assessment; which behavioral interventions have demonstrated efficacy; what placebo-controlled medication trials establish; and how the success of a research intervention changes when delivered in routine care. It also examines whether treatment outcomes measured by negative urine tests capture the broader phenomenon of recovery.
Its evidence base is organized around the WHO diagnostic framework World Health Organization (n.d.), the ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024), and original and synthesized evidence on intervention effects. Psychological mechanisms are used to interpret empirical observations; theoretical accounts are evaluated according to the distinct predictions and measurements they support. The current research does not justify treating a single brain image, craving score, or positive urine test as a complete explanation of individual addiction.
Evidence Selection and Scientific Method
This work is a critical narrative research synthesis. Its central materials consist of original experimental studies, controlled clinical trials, systematic reviews and meta-analyses, international classification documents, professional clinical guidelines, and public health surveillance. The source selection privileges papers with verifiable journal records, DOI links, registered designs where applicable, and sufficiently transparent methods to distinguish measured findings from author interpretation. It is neither a prospectively registered systematic review nor a newly conducted meta-analysis. Consequently it presents established pooled results from cited investigators rather than claiming to have exhaustively identified every eligible study or independently calculated pooled treatment effects.
Four classes of evidence answer different questions. Controlled laboratory studies can clarify acute reward and cognitive processes in defined exposure conditions. Randomized trials can estimate intervention effects for enrolled populations, assuming adequate allocation and outcome ascertainment. Cohort and registry research describe observed risk and long-term associations, with varying ability to identify causal pathways. Guidelines combine evidence assessment with professional judgments about clinical importance, feasibility, harms, and implementation. A conditional recommendation and a positive individual randomized trial are not interchangeable with a broadly established medication indication.
The empirical emphasis is on cocaine and methamphetamine. Other amphetamine-type stimulants enter where research combines participants across drug classes or when diagnostic distinctions require them. Opioid co-exposure is considered as a complication of drug supply and overdose prevention. Prescribed ADHD pharmacotherapy is treated only as a relevant differential and comorbid issue; its complete evidence belongs to a separate dossier.
Outcomes are interpreted by their measurement properties. A participant attending scheduled sessions may be retained in treatment without becoming abstinent. A participant reducing use may make clinically important gains even if the study's binary abstinence endpoint remains unmet. A urine specimen reflects a detection window and the sampling schedule; it is not a continuous recording of all substance use. Comparisons among studies must account for baseline use intensity, missing specimens, outcome timing, intervention intensity, and the distinction between treatment initiation and sustained recovery.
The clinical evidence is summarized as of November 3, 2026. Regulatory and prescribing information can change, so clinical practice remains governed by contemporaneous professional evaluation and current official labels. References are provided at the point of discussion and again in an alphabetically organized bibliography.
Historical Development of Stimulant Research
The history of stimulant disorders crosses pharmacological experimentation, changing medical practices, illicit markets, behavioral psychology, and the modern development of addiction medicine. Cocaine's incorporation into nineteenth-century medical experimentation and its subsequent movement through commercial and recreational environments made evident that the pharmacological properties of a substance interact with access and prevailing norms. Amphetamine compounds and methamphetamine later acquired their own histories through industrial synthesis, therapeutic use, wartime and postwar circulation, and changes in illicit production and distribution. These historical trajectories are important because prevalence and the social visibility of a disorder respond to supply, legality, route of administration, and health systems as well as to the actions of an individual drug molecule.
Modern experimental addiction science developed beyond a simple description of drug euphoria. Behavioral laboratories began asking whether drug effects functioned as reinforcers, whether environmental stimuli could acquire predictive and motivational significance, and whether controlled alteration of consequences could change substance-taking behavior. Clinical research then assessed observable endpoints such as retention, biologically verified abstinence, and return to use, while neuroimaging introduced measurable relationships between drug pharmacology and brain transporter occupancy.
An especially informative primary study is Volkow and colleagues (1997) Volkow (1997), which used positron emission tomography to study cocaine's occupancy of dopamine transporters and self-reported subjective drug effects in human participants. It provided a biological observation consistent with a dopamine-transporter mechanism, while remaining an experiment on acute drug effects rather than a direct demonstration of every process that constitutes a chronic use disorder. This distinction remains foundational for evaluating claims that a molecular event alone explains a complex behavioral syndrome.
Clinical behavioral research increasingly tested consequences as treatment variables. Rawson and colleagues (2006) Rawson (2006) directly compared contingency management, cognitive-behavioral approaches, and their combination among stimulant-dependent participants. The continuing development of contingency management reflects a methodological shift from exhorting abstinence toward designing environments that make verified recovery-related behaviors immediately and consistently consequential.
The later evidence-synthesis period introduced more rigorous comparisons among psychosocial modalities and pharmacotherapies. De Crescenzo and colleagues (2018) De Crescenzo (2018), Bentzley and colleagues (2021) Bentzley (2021), and the 2024 ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) are milestones in this process. They document advances in the evidence base alongside enduring limitations in medication development, implementation, study heterogeneity, and treatment access.
Diagnostic Frameworks and Clinical Boundaries
The World Health Organization's ICD-11 distinguishes disorders due to cocaine use (6C45) World Health Organization (n.d.) from disorders due to use of stimulants including amphetamines, methamphetamine, or methcathinone (6C46) World Health Organization (n.d.). These distinct categories preserve clinically important drug-class information. The ICD-11 also distinguishes harmful patterns, substance dependence, and other substance-related clinical states. Its separate treatment of an episode of harmful use, a harmful pattern, and dependence prevents a single event from being mistaken for the entire course of a chronic condition. Full diagnostic determination relies on the current WHO Clinical Descriptions and Diagnostic Requirements (2024) World Health Organization (2024).
The DSM-5-TR framework uses a dimensional approach to substance use disorders in which a constellation of impaired-control, social-impairment, risky-use, and pharmacological indicators informs diagnosis and severity. The meaning of any criterion depends on context. Tolerance or withdrawal may be present during exposure, but the observation of one physiological adaptation cannot replace the assessment of the full syndrome. Similarly, strong craving can influence prognosis and treatment planning without constituting a complete diagnosis in isolation.
A careful evaluation distinguishes the substance used, the current route and approximate temporal pattern, the person's reasons for use, functional consequences, attempts to reduce or cease use, the social consequences of use, psychiatric symptoms, and the course over time. Symptoms arising immediately after intoxication must be interpreted differently from symptoms present during extended abstinence. The same reported anxiety, insomnia, agitation, or persecutory belief can have different clinical explanations depending on temporal sequence, concurrent drugs, underlying disorders, and medical findings.
Differential assessment also includes whether a person is experiencing acute intoxication, withdrawal, a co-occurring mood or psychotic disorder, medication effects, or another medical condition. A confirmed substance use disorder may coexist with independent psychiatric diagnoses. Conversely, diagnostic overlap can arise because stimulant exposure itself changes sleep, appetite, attention, emotional regulation, and perception. The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) emphasizes a biopsychosocial assessment and concurrent care for co-occurring conditions.
The implications of diagnosis extend beyond classification. It establishes an organized framework for evaluating risk, impairment, and opportunities for care. The degree of impairment, the person's goals and resources, possible medical instability, and the availability of treatment all contribute to an appropriate care setting. The scientific construct is therefore simultaneously a diagnostic category and a longitudinal problem of psychological regulation.
Cocaine: Molecular Action and Behavioral Time Course
Cocaine exerts important central nervous system effects by inhibiting the reuptake of monoamines, particularly dopamine, through blockade of their transporters. Dopamine transporter blockade increases extracellular dopamine in circuits implicated in reward and motivation. Cocaine also affects norepinephrine and serotonin transporters, and its local anesthetic and cardiovascular properties produce clinical effects that are not reducible to dopamine alone. Its subjective and peripheral effects vary according to formulation, route, individual physiology, dose, frequency, and concurrent exposure.
The Volkow and colleagues (1997) PET study Volkow (1997) directly linked acute cocaine transporter occupancy with reported euphoria in a specific human experimental setting. The importance of this result lies in its measurement of a proposed mechanism. It does not imply that transporter occupancy predicts the development of dependence for every individual, or that a singular transporter measure captures choice, social reinforcement, psychosocial adversity, and long-term behavioral adaptation.
Rapid changes in brain exposure can increase the immediacy of reinforcement and make repeated administration behaviorally salient. Shorter subjective action, environmental availability, and route-dependent delivery can support clustered episodes of use. During sustained periods of exposure, the person may prioritize obtaining and consuming the substance while sleep, nutrition, financial security, work, and social obligations deteriorate. The precise sequence differs substantially among people, illustrating why the term binge is a behavioral description requiring temporal definition rather than an automatic diagnostic label.
Cocaine-related medical risk includes cardiovascular and cerebrovascular emergencies, arrhythmias, hyperthermia, and other acute complications. Cocaine-associated chest pain and neurological symptoms require medical assessment because the same presenting symptom can represent different pathophysiological emergencies. Cardiovascular burden can arise even when a person does not report a long history of compulsive use, an important distinction between exposure-related harm and diagnosed addiction. The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) treats potentially life-threatening intoxication complications as a separate priority from longitudinal addiction treatment.
The psychological implications of cocaine pharmacology are equally dynamic. Rapid reinforcement can coexist with distress, anxiety, sleep disruption, agitation, and diminished perceived control. Reward-related experiences during intoxication may be followed by dysphoria and renewed pursuit of the drug, but those patterns are shaped by learned cues, social situations, expectations, and personal vulnerability. No single pharmacological half-life determines the duration of a psychological disorder.
Methamphetamine: Monoamine Release and Extended Exposure
Methamphetamine and related amphetamine-type stimulants act through transporters and intracellular monoamine handling to increase monoaminergic neurotransmission. Methamphetamine's action differs mechanistically from cocaine's predominant transporter blockade: it facilitates transporter-mediated monoamine release and disrupts normal monoamine storage and clearance. This difference matters for the time course of exposure, the intensity and duration of behavioral activation, and the biological interpretation of repeated use.
Acute effects can include wakefulness, increased energy and activity, reduced appetite, and heightened arousal. Prolonged or repetitive exposure can be accompanied by marked sleep deprivation, weight loss, agitation, suspiciousness, and psychotic symptoms. The timing and severity of these observations depend on exposure, social circumstances, concurrent illnesses, and co-use of other substances. Vearrier and colleagues (2012) Vearrier (2012) assembled an extensive clinical and historical review of methamphetamine pharmacology and associated harms.
The distinction between neurobiological plausibility and evidence of permanent injury requires precision. Preclinical experiments demonstrate mechanistic pathways through which high or repeated exposure can disturb monoamine systems and cellular stress responses. Human imaging and neuropsychological studies reveal differences between some exposed and comparison groups, but causal interpretation is challenged by premorbid vulnerability, co-occurring substance use, sleep deprivation, variable abstinence, and selective recruitment. A cross-sectional imaging difference cannot determine when the difference arose or whether an intervention would reverse it.
Long periods of wakefulness also alter attention, impulsive control, threat perception, and social functioning independently of chronic neural adaptation. Accordingly, the psychological expression of methamphetamine-related problems is determined by interactions between pharmacology and rapidly changing physiological states. Sleep restoration, concurrent psychiatric assessment, medical stabilization, and continuing substance-use treatment are distinct domains of investigation.
Methamphetamine use disorder studies sometimes combine broad amphetamine-type stimulant populations, and their findings must be checked for class-specific applicability. The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) explicitly distinguishes cocaine-specific and amphetamine-type stimulant recommendations where trial evidence differs. A treatment effect established in a selected group with methamphetamine use disorder cannot be assumed equivalent for all cocaine users.
Reinforcement Learning, Cue Reactivity, and Motivational Organization
Reinforcement learning describes how the consequences of behavior change its future probability. In stimulant use, the immediate effects of a substance can reinforce actions that produce access to it, while places, people, objects, internal sensations, and expectations can acquire predictive significance through repeated association. These conditioned cues may increase attention to drug-related opportunities, evoke craving, and influence behavior long after an intoxication episode has ended.
A contemporary psychological account needs to distinguish primary drug effects from learned control by the environment. A drug-induced increase in extracellular dopamine is a pharmacological event. A learned response to an associated context is an acquired relationship between experience, prediction, and action. An episode of return to use after abstinence is a behavioral outcome that may involve stress, exposure opportunities, altered incentive value, habit, and shifting goals. These statements describe different causal targets and should be tested with different research methods.
Incentive-salience models propose that repeated drug exposure and learning can change the motivational pull of substance-related cues. Decision-making accounts further examine competition between immediate expected rewards and delayed, uncertain, or effortful alternatives. Habit-based and executive-control models investigate the degree to which familiar action sequences proceed with reduced prospective deliberation. Each model captures an aspect of the phenomenon; none licenses the assumption that individuals lose all capacity for evaluation or change.
Contingency management is a particularly important intervention because it tests behavioral principles under clinical conditions. Providing predictable reinforcement after objectively verified target behaviors alters the available reward structure. The effectiveness documented in randomized and synthesized treatment evidence demonstrates that learned patterns remain responsive to environmental change, even in the presence of strong pharmacological reinforcement. The theoretical rationale is supported by the experimental treatment literature, including Rawson et al. (2006) Rawson (2006) and De Crescenzo et al. (2018) De Crescenzo (2018).
Motivation also depends on belonging, employment, housing, the meaning of relationships, and perceived possibilities of life without the drug. Treatment systems that increase access to ordinary sources of reinforcement may therefore complement interventions targeting craving or behavior in a clinical session. This broader ecological perspective is compatible with learning theory while demanding evidence about the social environment and its consequences.
Craving, Inhibitory Control, and Psychological Heterogeneity
Craving refers to a subjective motivational state associated with the desire or urge to use a substance. It may be measured by self-report scales, experimentally elicited in cue-reactivity paradigms, or investigated through daily-life sampling. Its frequency, intensity, and relationship with actual use vary across individuals. A strong craving response does not mechanically produce substance use, and the absence of reported craving does not guarantee low clinical risk.
Inhibitory control has often been studied through response-inhibition tasks and decisions involving delayed outcomes. Findings of group differences can suggest alterations in cognitive control, but behavioral tasks measure performance under defined conditions rather than directly revealing a stable personal trait. Fatigue, withdrawal, medication effects, depression, anxiety, and socioeconomic strain may influence the very outcomes being interpreted as evidence of addiction-related dysfunction.
Psychological heterogeneity follows from distinct clinical histories. Some individuals primarily report cue-triggered craving, others use stimulants in relation to mood and social circumstances, and still others experience recurrent intoxication with severe psychiatric or medical complications. Some have co-occurring attention-deficit/hyperactivity disorder; others experience sleep disorders or trauma-related symptoms. Understanding the distribution of mechanisms is necessary for explaining variation in treatment response and retention.
Longitudinal repeated measurements offer a route beyond static classifications. Ecological momentary assessment can record changing cravings, circumstances, and affect in real-world contexts, while repeated toxicology and clinical interviews can characterize substance use. However, frequent measurement can itself influence behavior, adherence may depend on stability of housing or phone access, and self-report remains vulnerable to recall and social-desirability influences. A research program seeking individual prediction must test these biases explicitly rather than simply accumulating more observations.
Transition to Clinical Evidence
The mechanistic chapters establish why stimulant use disorders can involve cycles of exposure, reinforcement, withdrawal, cue sensitivity, and psychosocial disruption. The next part examines epidemiology, acute complications, psychiatric symptoms, outcome measurement, and clinical course. Its organizing principle is the separation of immediate exposure effects, established disorder, potential long-term consequences, and outcomes that clinical interventions can plausibly change.
Population Patterns, Surveillance, and Interpretation
Describing the epidemiology of stimulant use disorders requires defining whether a statistic concerns lifetime exposure, past-year use, clinically assessed disorder, treatment admission, emergency attendance, or death involving a named substance. These categories have different denominators, diagnostic meaning, and reporting systems. The World Health Organization's diagnostic scheme concerns clinically specified conditions, whereas national toxicology surveillance identifies drug involvement in deaths or other events. A death involving cocaine and fentanyl can appear under more than one drug category, and a substance detected after death does not prove that the deceased had met diagnostic criteria for a stimulant use disorder.
United States provisional mortality reporting illustrates these distinctions. The CDC's May 13, 2026 release Centers for Disease Control and Prevention (2026) estimated 26,181 deaths involving psychostimulants, including methamphetamine, and 19,581 involving cocaine during 2025; its corresponding provisional 2024 estimates were 29,852 and 22,397. These are substance-involved death estimates, with categories that can overlap. They are not independent counts of people with diagnosed stimulant use disorder, and the provisional series is subject to revision. The overall decline during that interval also does not imply that stimulant-related risks disappeared or became uniform across regions.
Cross-national comparisons are more difficult. The prevalence of cocaine, methamphetamine, and other stimulant markets differs by local distribution, regulatory arrangements, affordability, and route of administration. Diagnostic studies may employ different time frames and instruments, and many epidemiological surveys underrepresent people without stable housing, people in detention, and populations with high levels of acute health risk. Differences in police activity and toxicology testing can alter the apparent distribution of substances independently of the underlying incidence of disorder.
An epidemiological synthesis therefore joins multiple indicators. Survey estimates help characterize use patterns; clinical assessment identifies impairment; emergency and inpatient data represent severe complications among people reaching health services; and mortality surveillance addresses deaths involving specified drugs. Stable conclusions depend on matching the proposed claim to the measurement system, geography, year, and denominator. This principle applies with particular urgency to public narratives about epidemics and to claims that a newly observed trend reflects a new psychological mechanism.
Acute Intoxication and Medical Risk
Stimulant intoxication can present with sympathetic activation, agitation, anxiety, increased activity, altered judgment, and changes in sleep and appetite. Severe intoxication may involve hyperthermia, cardiac ischemia, arrhythmias, cerebrovascular events, seizures, severe hypertension, or delirium. Because physiological emergencies can arise during or after an episode of drug use, immediate medical risk must be evaluated independently from the longer-term work of treating a diagnosed use disorder.
The 2024 ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) describes acute life-threatening cardiovascular and metabolic complications requiring an appropriate level of care. It recommends assessment of agitation and psychosis for possible alternative causes and supports de-escalation and indicated medical management. Its recommendations are clinical decisions informed by observed presentation, staffing, monitoring facilities, and individual risk factors. They cannot be reduced to a universal medication recipe for readers.
Acute intoxication is also important for psychological evaluation because attention, perceptions, memory, and judgment may be changing rapidly. An interview conducted during severe agitation may capture the current state poorly and should be reinterpreted in longitudinal context. Reliable assessment can require subsequent interviews after stabilization, collateral clinical information where appropriate, and screening for co-ingested substances or concurrent illness.
Cocaine and methamphetamine do not produce identical time courses, and apparent behavioral similarities should not erase their mechanistic differences. A person with prolonged wakefulness and stimulant-associated paranoia presents different temporal questions from a person with episodic chest pain after cocaine exposure. Nonetheless, both patterns require systematic attention to physical safety and psychiatric symptoms before assuming that ordinary outpatient counseling alone addresses the current clinical situation.
This monograph describes warning signs to explain the scientific distinction between intoxication and longitudinal disorder. Severe chest pain, breathing difficulty, seizures, extreme hyperthermia, altered consciousness, or rapidly worsening psychosis are potential emergencies warranting urgent local medical response.
Withdrawal and the Post-Intoxication Course
After repeated or sustained stimulant exposure, cessation or reduction can be accompanied by fatigue, sleep disturbance, dysphoria, appetite changes, psychomotor slowing or agitation, intense craving, and changes in perceived energy or reward. These symptoms may shift over time and vary substantially between people and drug-use patterns. Sleep and mood can be strongly affected by the duration of prior wakefulness and the cumulative burden of physical stress.
A conceptual distinction is necessary between acute withdrawal symptoms and a prolonged period of psychological and social readjustment. The first concerns a temporally associated clinical syndrome after cessation or reduction. The second includes the gradual restoration of ordinary routines, management of environmental triggers, treatment of co-occurring disorders, and rebuilding of work, housing, or relationships. A clinician may appropriately treat both, but they are not the same measurement target.
Acheson and colleagues (2023) Acheson (2023) conducted a systematic review and meta-analysis of randomized trials investigating pharmacological approaches to methamphetamine withdrawal. The existence of randomized investigations does not establish a broadly effective medication for every withdrawal symptom or a standardized drug regimen. Heterogeneity of interventions, samples, and study outcomes limits conclusions. The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) emphasizes clinical monitoring and treatment of symptoms that interfere with engagement, including depression, anxiety, insomnia, and paranoia that may persist beyond the immediate withdrawal interval.
Withdrawal research faces several measurement difficulties. Retrospective estimates of symptom onset may be inaccurate, particularly in polysubstance use. The timing of the last use may not be reliably documented. Depression may reflect independent illness, withdrawal, or both. Laboratory toxicology measures exposure during a detection window but does not directly measure the cause of the person's mood or cognitive symptoms.
Distinguishing these possibilities is essential to both sound inference and safe clinical care. The most informative investigations follow symptoms over time, establish the pattern of substance exposure, and evaluate alternative causes. They also recognize that suicidal thinking can emerge or worsen around intoxication offset or withdrawal, making psychiatric safety evaluation an integral part of care.
Psychosis, Paranoia, and Differential Diagnosis
Stimulant-associated psychotic symptoms include persecutory interpretations, hallucinations, and other disruptions in reality testing that may emerge during intensive use or associated sleep deprivation. These phenomena are particularly important in methamphetamine research but also occur in cocaine-related clinical presentations. Their occurrence does not alone establish a primary schizophrenia-spectrum disorder, just as the presence of stimulant exposure does not rule one out.
The clinical problem is longitudinal and differential. The temporal relationship between use and symptoms, the persistence of symptoms during abstinence, prior episodes, family and psychiatric history, cognitive change, sleep deprivation, and co-occurring substances all affect assessment. A diagnosis made during an acute episode may require subsequent review as additional evidence emerges. The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) recommends treating symptoms of psychosis or mania with indicated medication, evaluating other possible causes, and monitoring psychiatric safety.
Research descriptions of stimulant-induced psychosis must distinguish point prevalence during active use, lifetime history of symptoms, incident psychosis, and enduring psychotic disorders. Study samples recruited from emergency departments or psychiatric inpatient settings are enriched for severe presentations. Their estimates cannot be transferred to the entire population of people who have used stimulants. Clinical service data also reflect help-seeking, bed availability, and diagnostic conventions.
Several theoretical mechanisms can contribute to vulnerability: intense catecholaminergic stimulation, sleep deprivation, stress, preexisting psychiatric liability, and sensitization of responses to repeated exposure. The relative contributions cannot be inferred solely from co-occurrence in a cross-sectional sample. Scientific models must be tested longitudinally and, where feasible, against appropriate comparison groups.
In clinical care, the distinction between psychosis and immediate danger remains crucial. Acute disorganization, severe agitation, self-harm risk, or medical instability requires an appropriately equipped care setting. Effective addiction treatment then addresses the recurrent exposure and the wider conditions that may precipitate further episodes.
Cardiovascular, Neurological, and Other Physical Harms
The cardiovascular effects of stimulants are clinically central because their serious complications may be abrupt and may coexist with a long history of use. Vasoconstriction, increased heart rate and blood pressure, myocardial oxygen demand, arrhythmogenic factors, and thrombotic mechanisms are relevant to cocaine-associated acute coronary and cerebrovascular events. Methamphetamine exposure may also be associated with cardiovascular morbidity, including cardiomyopathy, arrhythmias, and vascular complications. Interpretation requires distinguishing observed clinical associations from the causal contribution of coexisting cardiovascular risk factors and other drugs.
The ASAM/AAAP clinical guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) highlights the need to consider cardiac and renal disorders among people with prolonged heavy stimulant exposure. It discusses clinical indications for electrocardiographic assessment and evaluation for rhabdomyolysis, depending on the presentation. These decisions belong to healthcare professionals using appropriate medical testing, not to fixed assumptions drawn from a research article.
Additional concerns include oral health, nutrition, infectious disease exposure associated with injection or sexual risk contexts, skin injury, and sleep disruption. Some risks are produced primarily by the drug's physiological effects; others arise from route of administration, lack of access to healthcare, environmental exposure, or social circumstances. The scientific aim is to identify the relevant pathway so that prevention and treatment target the causal conditions rather than merely reproducing an undifferentiated list of harms.
Polydrug exposure further complicates diagnosis. Illicit drug supplies may contain unexpected opioids or other substances, including agents that alter toxicity. The source and composition of a product are frequently uncertain, making a person's reported intended substance an incomplete indicator of actual exposure. The ASAM resource on stimulant use disorder American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) addresses contamination and the compounded risk of opioid co-exposure.
Good clinical studies therefore report route and frequency of use, diagnostic status, other substance involvement, preexisting medical conditions, and outcome ascertainment. Without these details, findings may establish an association between a group and an outcome but cannot specify how much risk is independently attributable to a named stimulant.
Sleep, Cognitive Functioning, and Emotional Regulation
Sleep disturbance links stimulant pharmacology with psychological functioning across several timescales. Acute wakefulness can impair attention, memory, impulse control, threat appraisal, and emotional stability. Prolonged sleep restriction may intensify unusual perceptual experiences and worsen interpersonal conflict, while subsequent sleep rebound changes the clinical appearance. These phenomena are themselves significant consequences of exposure, whether or not a persistent neurocognitive disorder develops.
Neuropsychological studies have examined learning, working memory, sustained attention, inhibition, reward valuation, and flexible decision-making in populations with stimulant-use histories. Their findings are heterogeneous. Performance differences may reflect differences present before substance exposure, concurrent psychiatric problems, current withdrawal, residual drug effects, sleep, education, trauma, or selective enrollment. Reverse causation is a major challenge because traits associated with substance initiation can also predict laboratory performance.
The scientific distinction between state and trait is decisive. Measuring a person shortly after intensive use tests a different psychological condition from measuring the same person after months of verified abstinence. Even repeated testing requires accounting for practice effects, selective dropout, and changes in medical or social circumstances. A high-quality longitudinal design should describe the exposure history and the time elapsed since last use, rather than treating any positive result as proof of enduring brain damage.
Clinical interventions can plausibly improve functioning through several pathways: reducing exposure, restoring sleep, treating co-occurring symptoms, improving psychosocial stability, and strengthening daily organizational supports. Whether a particular intervention produces durable neurocognitive gains is a separate empirical question that needs appropriately controlled follow-up.
Co-Occurring Psychiatric Conditions and Polysubstance Use
Stimulant use disorders frequently intersect with mood disorders, anxiety conditions, trauma-related symptoms, attention-deficit/hyperactivity disorder, and other substance use disorders. Co-occurrence creates diagnostic and therapeutic challenges because both the stimulant disorder and an independent condition can contribute to apparently similar symptoms. Depression might precede stimulant use, emerge during withdrawal, or arise through a more complex reciprocal trajectory. Determining temporal order requires more than a single assessment.
The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) recommends treating stimulant use disorder and co-occurring psychiatric or substance use disorders concurrently, with integrated behavioral treatment where possible. Co-occurring ADHD is especially relevant to interpreting the presence of prescribed stimulant medication. A prescription and monitored therapeutic use are distinct from unregulated exposure or compulsive use; when both ADHD and stimulant use disorder are diagnosed, treatment decisions require specialist attention to efficacy, misuse risk, and monitoring.
Opioid exposure is equally significant in contemporary drug markets. Some patients have an independent opioid use disorder; others experience unintended opioid exposure when a non-opioid product is contaminated. This changes overdose risk and the clinical needs of the individual. Evidence-based opioid use disorder treatment and overdose prevention should be provided according to their own indications alongside stimulant treatment.
Integrated treatment is a researchable service model rather than a synonym for simply listing every comorbidity. Its effectiveness depends on whether patients can receive coordinated evaluations, attend care, obtain medications where indicated, maintain behavioral treatment, and access basic support. Studies should assess whether such coordination improves retention, symptom burden, substance-use outcomes, and functioning compared with fragmented care.
Assessment Instruments and Measurement Validity
A comprehensive evaluation includes diagnostic interviews, use-frequency timelines, clinical assessment of impairment, cravings and withdrawal symptoms, psychiatric safety assessment, and measurement of functional outcomes. None of these instruments is interchangeable. A validated diagnostic interview estimates a syndrome, an urge rating estimates a current subjective state, and a biological assay detects particular compounds or metabolites during an assay-specific window.
Urine drug testing is common in controlled treatment trials because it can provide an objective indicator of recent exposure. Yet its interpretation depends on collection frequency, assay detection windows, reporting thresholds, missing specimens, and the possible presence of prescribed medications or contaminants. A negative specimen may be compatible with prior use outside the detection window. A positive specimen confirms exposure within the relevant detection conditions but does not directly indicate the degree of impairment at a particular moment.
This measurement issue becomes especially important for contingency management, in which objective verification is part of the intervention itself. Trials must report what behavior triggered reinforcement, when specimens were obtained, how missed visits were coded, and how rewards were delivered. Otherwise it may be impossible to reconstruct the treatment mechanism or compare studies with differing schedules.
Treatment outcomes should also include retention, frequency and intensity of use, physical and psychiatric harms, quality of life, housing or employment stability, social functioning, and patient-defined goals. A single abstinence endpoint offers useful standardization but may miss changes that are meaningful for safety and recovery. An unusually broad composite measure, however, can conceal the failure of a specific predefined primary outcome.
Longitudinal Course, Recurrence, and Remission
Stimulant use disorders often fluctuate over time rather than following a uniform trajectory. Periods of sustained use may alternate with reductions, abstinence, recurrence, or extended remission. Interpreting the course requires a clear observation window, consistent definition of return to use, and acknowledgment that people may improve on several domains while continuing to face other risks.
Recurrence after treatment may reflect renewed exposure to cues, stress, diminished access to alternative rewards, psychiatric symptoms, or changes in social relationships. These are plausible pathways that vary in individual importance. A laboratory demonstration of cue reactivity does not establish that a particular episode of recurrence was caused by a single cue. Longitudinal behavioral observations, prospective assessment, and carefully analyzed clinical histories are needed to identify actionable patterns.
A strong treatment evaluation distinguishes immediate end-of-program effects from durability. Reinforcement delivered during contingency management may yield rapid improvements, but studies need sufficiently long follow-up to determine the persistence of benefit after incentives stop. Combining CM with community reinforcement and skills-based treatment offers a theoretical rationale for durability; the magnitude and generalizability of long-term effects must be assessed empirically.
Recovery is best studied as a multidimensional process involving changes in use, health, functioning, personal stability, relationships, and access to care. This permits evaluation of improvements that are clinically important even before complete remission, while maintaining clarity about the primary endpoints of a particular trial.
The Transition from Assessment to Intervention Evidence
The reviewed clinical literature establishes several separate treatment targets: acute physiological danger, withdrawal burden, psychotic or mood symptoms, recurrent stimulant use, access to care, and the environmental conditions influencing sustained recovery. A single intervention is unlikely to address all of them equally. The following treatment chapters therefore examine behavioral and pharmacological evidence with attention to the clinical population, outcome definition, causal inference, comparative effectiveness, and implementation setting.
Evidence-Based Treatment: General Principles
The central treatment question is which interventions reliably improve outcomes for people living with cocaine or methamphetamine use disorder, for whom, through which mechanisms, and over what interval. Pharmacological plausibility alone does not answer this question. A therapy may reduce craving scores without demonstrably reducing drug exposure; another may increase negative toxicology results during a twelve-week program without establishing sustained recovery or a reduction in medical complications. Treatment effectiveness must be examined using outcomes appropriate to the claim.
The ASAM/AAAP Clinical Practice Guideline (2024) American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) identifies contingency management as the strongest-supported psychosocial component of treatment for stimulant use disorder. It also identifies cognitive behavioral therapy, the community reinforcement approach, and the Matrix Model as relevant interventions that may complement contingency management. Guideline recommendations integrate the quality of evidence with considerations of feasibility and patient need, so a ranking of empirical support does not mean every component is required in an identical sequence for all patients.
Treatment intensity and setting must match the person's condition. Medical or psychiatric instability, co-occurring disorders, withdrawal burden, safety concerns, and access to reliable support influence whether care is offered in outpatient, intensive, inpatient, or other settings. Individualized planning involves collaborative goals, assessment of functional harms, and the capacity to reassess if symptoms or risks change.
The treatment literature has historically emphasized abstinence and retention, both clinically important but incomplete endpoints. Work, sleep, relationships, infectious disease risk, cardiovascular safety, emotional functioning, and reduced exposure to contaminated drug supplies may improve even when categorical remission has not yet been achieved. Such outcomes must be defined beforehand and evaluated with suitable controls. The monograph's purpose is to explain why some interventions have more reliable evidence than others, rather than to prescribe a regimen for an individual reader.
Contingency Management: Mechanism and Clinical Design
Contingency management, or CM, uses predictable, timely reinforcement contingent on objectively specified recovery-related behaviors, commonly verified abstinence or participation targets. Its theoretical basis derives from operant learning: behavior becomes more likely when followed by a valued consequence under conditions the participant understands. In clinical programs, reinforcement may involve vouchers, prize opportunities, or other structured incentives, with safeguards concerning fairness, verification, and the appropriateness of the chosen target.
CM is a treatment technology with active parameters. The relationship between the target behavior and reward must be explicit; verification must be reliable; reinforcement must be delivered consistently; and the program must account for missed visits or administrative barriers. The effective treatment is therefore more than offering a gift or rewarding good intentions. Timing, magnitude, escalation, and opportunity for reengagement can affect the way reinforcement interacts with drug-related rewards.
In the randomized study by Rawson and colleagues (2006) Rawson (2006), contingency management was compared with cognitive behavioral treatment and their combination among participants with stimulant dependence. The trial demonstrates the importance of experimentally comparing different behavioral approaches rather than assuming a common theoretical foundation translates automatically into equivalent outcomes.
Brown and DeFulio (2020) Brown (2020) systematically reviewed contingency management for methamphetamine use disorder. Their synthesis strengthens the conclusion that the intervention is more than a single-clinic innovation, but variations in intervention design, populations, and follow-up still matter. The ASAM/AAAP guideline (2024) American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) describes CM as the current standard of care and recommends that it form a primary component of the treatment plan, often with other psychosocial therapies.
Clinical implementation requires distinguishing incentives delivered to change clinically meaningful behavior from financial support unrelated to a target. It also requires protecting privacy, minimizing coercion, ensuring understandable rules, and avoiding conditions in which a person is punished for unstable access to transport or accommodation. Equity and treatment fidelity can be evaluated jointly rather than treated as competing aims.
Comparative Evidence for Psychosocial Interventions
The strongest comparative conclusions emerge from studies that place treatments in a common evidence framework while explicitly handling differences in trial designs. De Crescenzo and colleagues (2018) De Crescenzo (2018) conducted a systematic review and network meta-analysis of 50 randomized trials involving 6,942 participants with cocaine or amphetamine addiction. The review examined 12 psychosocial interventions or treatment as usual. The combination of contingency management and the community reinforcement approach was the only intervention in that network associated with greater abstinence than treatment as usual at end of treatment, twelve weeks, and longest follow-up, although effect estimates and certainty differed across outcomes and comparisons.
A principal quantitative result was the end-of-treatment abstinence comparison for CM plus community reinforcement versus treatment as usual, with an odds ratio of 2.84 and a 95% confidence interval from 1.24 to 6.51. The estimate should be interpreted against its actual endpoint, network assumptions, and uncertainty. Network estimates are not equivalent to a single randomized head-to-head experiment, and indirect comparisons require sufficient similarity across populations and treatment settings. The authors identified study quality and difficulty blinding psychosocial interventions as relevant limitations.
A broader cocaine-specific analysis by Bentzley and colleagues (2021) Bentzley (2021) synthesized 157 clinical trials comprising 402 treatment groups and 15,842 participants. Among the evaluated categories, contingency management was the only treatment class significantly associated with a higher likelihood of negative cocaine toxicology results at end of treatment. The reported odds ratio was 2.13 (95% confidence interval, 1.62–2.80). The outcome concerned observed cocaine-negative samples under the included study designs and did not establish a permanent cure.
The findings are complementary rather than identical. The De Crescenzo review examined a network of structured psychosocial comparisons for both cocaine and amphetamine addiction, while Bentzley and colleagues focused on a broader collection of cocaine treatment studies and a different meta-analytic framework. Differences in included studies, outcome definitions, analytic methods, and treatment grouping require preserving the distinct estimates instead of pooling them informally.
The weight of evidence supports making CM accessible and combining it with other evidence-based psychosocial treatment where feasible. It also reveals a public-health research challenge: the treatment with the most consistent evidence is often underimplemented, so effectiveness in controlled studies must be connected to financing, staffing, service delivery, and patient access.
Community Reinforcement and Everyday Alternatives to Drug Reward
The community reinforcement approach, or CRA, aims to change the broader pattern of reinforcement sustaining a person's daily life. Its clinical components can address work, social interaction, leisure, family relationships, and practical problem solving so that substance-free activities become more available and rewarding. The mechanism is not restricted to suppression of drug-related cues; it involves making adaptive alternatives more attainable and reinforcing.
CRA's explanatory relevance follows from the fact that drug use is embedded in an ecology of opportunities. When personal routines are dominated by unstable housing, exposure to drug-selling contexts, isolation, or few rewarding alternatives, simple advice to pursue abstinence leaves much of the behavioral environment intact. A community reinforcement strategy seeks measurable change in that environment.
De Crescenzo et al. (2018) De Crescenzo (2018) found particularly favorable evidence for the combination of CM with CRA. The importance of this result is methodological as well as practical: it suggests that immediate reinforcement for target behaviors and broader restructuring of ordinary sources of reward can be productively studied together. Still, any claim that their effects are necessarily additive or synergistic requires direct tests of component contributions.
Good future research should distinguish which CRA components are delivered, their intensity, the characteristics of community resources, and the durability of improvement after formal treatment ends. Contextual constraints can prevent participants from accessing employment or safe activities regardless of therapeutic motivation, so social support availability must be measured rather than assumed.
Matrix Model, Structured Care, and Treatment Engagement
The Matrix Model is a structured treatment approach associated historically with stimulant treatment programs and combining elements such as cognitive behavioral methods, relapse prevention, family education, group support, and urine monitoring. The relevant scientific question concerns the consequences of a coordinated package of services for a defined population, rather than assuming each individual component has been independently validated through the same trial.
The SAMHSA Treatment Improvement Protocol 33, updated in 2021 Substance Abuse and Mental Health Services Administration (2021), reviews behavioral treatment options and practice considerations, including structured approaches for stimulant use. The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) lists the Matrix Model among psychosocial interventions that can accompany CM, with a conditional recommendation reflecting its assessment of the evidence.
Group delivery, education, and structured contact can support engagement, but research must separate increased clinic attendance from reduced drug use, and reduced use from improvements in social functioning. Multi-component programs also create attribution challenges: a beneficial outcome may reflect greater clinician contact, more frequent toxicology monitoring, the support group, contingency management, or interactions among these components.
An appropriate comparative trial should describe treatment fidelity, component exposure, attrition, follow-up, and background care. Without such reporting, a statement that a named model was effective can become too vague to explain what should be reproduced in another clinical setting.
Pharmacotherapy for Cocaine Use Disorder
Medication research for cocaine use disorder has investigated agents targeting catecholamine systems, mood and anxiety symptoms, glutamatergic regulation, and other proposed mechanisms. Several candidates have shown signals in particular trials or subgroups, but the therapeutic status of those findings must be understood through evidence quality, replication, safety, and regulatory authorization. As of the guideline and regulatory materials reviewed for this monograph, no medication has an FDA-approved indication specifically for cocaine use disorder.
Chan and colleagues (2019) Chan (2019) systematically reviewed and meta-analyzed pharmacotherapy for cocaine use disorder. Their analysis is important because it synthesizes outcomes across drug classes and makes visible the limitations of small heterogeneous studies. An apparently favorable subgroup estimate may be driven by treatment context, baseline comorbidity, or risk of bias; it cannot establish routine efficacy across all people with cocaine use disorder.
The ASAM/AAAP guideline (2024) American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) conditionally suggests that clinicians may consider bupropion to promote abstinence and topiramate to reduce use for selected patients with cocaine use disorder, based on low-certainty evidence. The guideline also discusses possible relevance of co-occurring tobacco use, depression, or alcohol use disorder in treatment planning. Such suggestions are off-label clinical judgments and do not confer an approved indication.
The comparison between behavioral interventions and medication trials is instructive. CM has substantial and relatively consistent evidence for selected short-term cocaine outcomes, whereas medication findings are more fragmented and usually less certain. This is a conclusion about the current strength of evidence, not a claim that pharmacological research is intrinsically futile. Mechanistic heterogeneity, trial design, adherence, and psychiatric comorbidity remain legitimate targets of future medication development.
Clinical use of any pharmacotherapy requires professional evaluation of contraindications, interactions, potential harms, co-occurring disorders, and current labeling. This manuscript does not specify a prescription plan, dose, or duration for a reader.
Methamphetamine Pharmacotherapy: Naltrexone and Bupropion
A landmark placebo-controlled study is Trivedi and colleagues' 2021 ADAPT-2 trial Trivedi (2021), which investigated extended-release injectable naltrexone combined with oral extended-release bupropion for adults with moderate or severe methamphetamine use disorder. The multicenter study employed a sequential parallel comparison design rather than a conventional single-stage two-arm comparison. It assessed a prespecified response based on methamphetamine-negative urine specimens toward the end of each six-week stage.
The weighted response was 13.6% in the active-treatment condition and 2.5% in the placebo condition, with an estimated difference of 11.1 percentage points. The study demonstrated a statistically significant advantage for the combination on its predefined endpoint. The absolute response remained low, an important reminder that a positive randomized result does not equate to reliable response for most treated participants.
The trial's population, protocol intensity, medication adherence arrangements, screening requirements, outcome timing, and exclusion criteria limit straightforward generalization to every clinical setting. The combination also presents distinct safety considerations and should not be interpreted as approval of an unsupervised regimen. In particular, opioid exposure and naltrexone eligibility require careful medical evaluation, while bupropion has its own contraindications and safety profile.
The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) gives a conditional recommendation for considering bupropion plus naltrexone in amphetamine-type stimulant use disorder, with moderate certainty for the specified recommendation. It also includes conditional, generally lower-certainty recommendations for selected other medications. The guideline distinguishes specialist clinical discretion from regulatory approval.
For evidence synthesis, the ADAPT-2 result should be described precisely: the trial established an effect on a defined toxicology-based response in the studied population over twelve weeks. It did not prove that all individuals with methamphetamine use disorder benefit, that effects persist indefinitely, or that the combination is an approved standalone treatment for this diagnosis.
Methamphetamine Pharmacotherapy: Mirtazapine and Other Candidates
A related medication research program investigates mirtazapine, which has established antidepressant uses and pharmacological effects relevant to sleep and affective symptoms. Colfax and colleagues (2011) Colfax (2011) conducted a randomized placebo-controlled trial in sexually active men who have sex with men and were using methamphetamine. The study reported a reduction in methamphetamine-positive urine outcomes in the active-treatment arm under its trial conditions.
Coffin and colleagues (2020) Coffin (2020) subsequently tested mirtazapine in a placebo-controlled trial involving cisgender men and transgender women who have sex with men. This program supplies evidence that deserves attention while remaining limited by specific recruitment populations, care settings, and the need to evaluate effectiveness in a more diverse range of patients.
The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) allows clinicians to consider mirtazapine for some people with amphetamine-type stimulant use disorder under a low-certainty conditional recommendation, with possible additional relevance to co-occurring depression. The recommendation does not establish routine first-line medication efficacy.
Other investigated treatments include bupropion alone, topiramate, and selected psychostimulant approaches under specialized supervision. Each intervention raises its own comparison between plausible action, actual controlled evidence, adherence, misuse and cardiovascular risks, and feasibility in routine practice. Prescribing controlled psychostimulants for stimulant use disorder requires specialist expertise and capacity for close monitoring according to the ASAM/AAAP guideline.
The central synthesis is that medication development has produced informative but heterogeneous signals. Psychological treatment with CM remains the best-supported core intervention, while pharmacotherapies should be considered through the exact evidence and clinical circumstances of each candidate rather than as one undifferentiated medication class.
Integrated Care, Harm Reduction, and Continuity
Effective treatment systems respond to health and social consequences as well as drug-use outcomes. Integrated care may address withdrawal-related symptoms, psychiatric comorbidity, HIV and viral hepatitis prevention, cardiovascular monitoring, nutrition, sleep, dental care, smoking, housing, and available family or community supports. This integrated orientation does not require that every participant receive the same intervention; it means relevant problems are assessed and coordinated rather than ignored because they fall outside the addiction clinic's narrow specialty.
For individuals at risk of exposure to opioid-contaminated supplies, overdose education, access to naloxone according to local practice and availability, and referral for opioid use disorder treatment when indicated can be important components of prevention. Naloxone reverses opioid overdose; it is not a pharmacological antidote to isolated stimulant toxicity. Its relevance arises from possible opioid co-exposure. The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) emphasizes secondary and tertiary prevention strategies tailored to identified risks.
Telehealth and technology-supported interventions may lower practical barriers to some behavioral treatments. The guideline recommends considering telemedicine for patients who face challenges accessing in-person care and permits evidence-based digital treatment as an adjunct rather than an assumed replacement for appropriate clinical services. Digital platforms can support appointment reminders, data collection, or reinforcement administration, but their actual efficacy depends on tested implementation, privacy safeguards, and patient usability.
Treatment access also depends on financing and service organization. An intervention that is highly effective in trials but unavailable to most patients produces a substantial effectiveness gap. Implementation research should examine costs, fidelity, workforce training, incentive administration, monitoring burden, and whether the intervention reaches people with unstable housing or irregular work schedules.
Youth, Pregnancy, and Other Special Populations
Adolescents and young adults require developmentally responsive clinical engagement, attention to family and school contexts, and careful evaluation of confidentiality and safety. Findings obtained primarily in adult stimulant trials cannot be mechanically applied to minors. The ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024) calls for access to appropriate treatment and harm-reduction services for younger populations with attention to developmental needs.
Pregnancy introduces additional medical and ethical considerations. The implications of stimulant exposure, withdrawal, co-occurring illnesses, prenatal care access, and psychosocial stress require qualified obstetric and addiction care. Observational associations between exposure and pregnancy outcomes may be confounded by other substances, smoking, nutrition, poverty, and healthcare access. Causal claims therefore need careful adjustment and transparent discussion of residual uncertainty.
Treatment research among populations experiencing homelessness, incarceration, or unstable healthcare access presents additional selection and follow-up problems. Requirements for frequent clinic attendance or phone-based monitoring may exclude those at greatest risk. If a program is evaluated only among highly adherent participants, its estimated efficacy may not characterize the patients for whom implementation difficulties are greatest.
Equity-conscious trial design should measure differential enrollment, dropout, adherence, and response across relevant groups without turning demographic categories into unsupported biological explanations. Adaptations should be tested for both cultural acceptability and preservation of the mechanism that makes the intervention effective.
Recovery Outcomes and Treatment Implementation
A high-quality implementation framework connects evidence-based mechanisms to actual service delivery. For contingency management, the intervention requires operational verification, reinforcement delivery, understandable rules, and a sustainable funding model. For CBT, it requires trained practitioners, intervention fidelity, suitable session availability, and the capacity to accommodate co-occurring psychiatric conditions. For CRA, it requires real access to alternative sources of reinforcement. Treatment availability on paper is not equivalent to effective delivery.
Implementation outcomes should include reach, adoption, fidelity, retention, equity, and sustainability alongside patient-level results. Programs may achieve high uptake initially while struggling with long-term financing or staffing. Similarly, a program can preserve the label CM while delivering incentives too inconsistently to reproduce the conditions studied in randomized trials.
The 2026 JAMA Internal Medicine discussion by Kennedy, Bhatraju, and Chan Kennedy (2026) describes the gap between the evidence supporting CM and its utilization in ordinary clinical practice. This implementation gap is a major scientific problem because differences between efficacy and effectiveness can dominate the ultimate population benefit of a treatment.
Technology can reduce some coordination costs but introduces new requirements for privacy, accessibility, algorithmic reliability, and fair access to devices. In the Artificial Era, automated monitoring and feedback systems may become additional research objects. Their evaluation should specify which decisions are automated, how records are validated, what humans supervise, and whether the technology improves independently assessed outcomes. Claims of therapeutic agency or autonomous clinical decision-making require their own empirical demonstration.
Synthesis of Treatment Evidence
The strongest supported clinical conclusion is that contingency management should be central to evidence-based psychosocial treatment for stimulant use disorder, with additional behavioral modalities selected according to patient needs and resources. Systematic reviews and clinical guidelines converge on this point, although certainty differs for precise comparisons, special populations, and durable outcomes. CRA, CBT, and the Matrix Model each address complementary clinical functions and require faithful implementation.
Pharmacotherapy currently offers a developing and heterogeneous evidence base. The naltrexone–bupropion combination has demonstrated a statistically significant methamphetamine-specific trial benefit with a low absolute response rate. Mirtazapine and other medications have evidence signals in defined populations; recommendations remain conditional and off-label. For cocaine use disorder, the efficacy evidence for CM is materially more consistent than the medication literature reviewed. Medication research is important precisely because more effective and widely generalizable treatments are still needed.
The service-level conclusion is that treatment must be evaluated as a coordinated process rather than a single intervention label. Outcomes depend on clinical safety, psychiatric care, reinforcement structure, access, continuity, implementation quality, and the social environment to which a patient returns.
Critical Analysis of Evidence Quality
The research literature provides evidence at several levels of certainty, and any synthesis must preserve those distinctions. At the strongest level for a particular treatment question are adequately designed randomized comparisons with clinically interpretable outcomes and reproducible findings. For stimulant use disorders, the repeated support for contingency management in controlled studies and independent systematic syntheses justifies its central position in professional guidelines. This conclusion is anchored in measured changes in use and treatment engagement rather than in a claim that every person benefits or that gains are permanently maintained.
Evidence certainty becomes more limited when studies are small, interventions vary considerably, attrition is high, investigators cannot maintain adequate outcome verification, or long-term follow-up is insufficient. In psychosocial trials blinding the person or clinician to treatment allocation is often impossible; using biological outcomes can help reduce some measurement biases, but it does not eliminate selection, dropout, expectancy, or differences in treatment intensity. De Crescenzo et al. (2018) De Crescenzo (2018) explicitly evaluated bias and certainty within this context.
Medication studies face overlapping and additional difficulties: heterogeneous baseline use frequency, differing psychiatric comorbidity, adherence to a complex regimen, selected participants, adverse events, and use of treatment packages in which contact intensity or concurrent behavioral care differs. A successful primary endpoint must be interpreted with its absolute response rate, follow-up duration, and safety information. The ADAPT-2 study Trivedi (2021) is exemplary in reporting its two-stage design and prespecified composite response, and it illustrates why a statistically credible effect may still represent an incomplete therapeutic solution.
Biological and observational research is essential for understanding mechanisms and harm, but its causal interpretations are more constrained. People who use stimulants may differ from comparison participants before exposure; medical complications may be influenced by other substances, social conditions, or the timing of assessment. Similarly, clinical severity can influence the likelihood of entering treatment, making service-based samples unrepresentative of the whole population with disorder.
A scientifically valid synthesis should therefore reject both premature therapeutic certainty and the assumption that inconclusive findings imply the absence of potentially useful mechanisms. Evidence warrants separate claims about biological plausibility, symptomatic improvement, objective reduction in use, clinical risk, and sustained functional recovery.
Unresolved Theoretical and Experimental Problems
Several research problems deserve sustained investigation. First, the relation between reinforcement learning and longer-term motivational organization is incompletely resolved. Cue effects are observable under experimental conditions, but personalized prediction of recurrence across changing social environments remains difficult. Studies need to link laboratory measures with repeated real-world behavior while maintaining validation against outcomes that matter clinically.
Second, more evidence is needed on the persistence and reversibility of psychiatric and cognitive changes. Cross-sectional imaging studies cannot by themselves distinguish preexisting vulnerability from consequences of use. Prospective designs with adequate control for sleep, trauma, psychiatric illness, and polysubstance exposure are necessary. Evidence on persistent stimulant-associated psychosis also requires longitudinal differential assessment, not a one-time symptom checklist.
Third, treatment-durability research must establish what happens after reinforcement programs end. Some patients may maintain gains because alternative rewards and coping abilities have become more established; others may experience recurrence when environmental contingencies change. Direct comparisons of CM schedules, combinations with CRA or CBT, and carefully documented long-term follow-up are needed.
Fourth, the clinical translation of pharmacotherapy trials remains unresolved for many populations. Confirmatory studies should assess absolute benefit, clinically meaningful harms, adherence, functional outcomes, and the effects of co-occurring disorders. Candidate biological markers would be useful only if they predict differential treatment benefit beyond simpler clinical variables and replicate in independent samples.
Fifth, population-level benefit depends on implementation. Researchers should treat underuse of effective CM as a scientific problem of funding, access, incentives, healthcare organization, and treatment fidelity. Studies of technology-supported delivery should report privacy, equity, usability, and the degree to which automated decision systems preserve clinical oversight.
Sixth, research must adjust to the reality of polydrug exposure and unstable illicit drug supply. Reliance on self-reported intended stimulant alone risks misclassifying actual pharmacological exposure. Better toxicology, explicit geographic and temporal reporting, and integration of harm-reduction outcomes are crucial to estimating risk and evaluating interventions.
Methodological Priorities for the Next Research Cycle
Future clinical trials should preregister primary outcomes and analysis plans, report randomization and missing-data handling, provide sufficient information about intervention fidelity, and avoid changing endpoint definitions after results become visible. For toxicology-based outcomes, reporting should include assay type, detection window assumptions, testing frequency, missed-visit treatment, and whether treatment arms had equivalent opportunities for specimen collection.
Trials of complex behavioral interventions should describe their active components and compare plausible alternative explanations, including increased clinical contact and monitoring. Studies evaluating technology-delivered contingency management should document how participant identity, sample validity, incentive allocation, and accessibility were established. The appearance of technical precision does not guarantee measurement validity.
Longitudinal research should combine repeated exposure measures, functional assessments, psychiatric evaluation, and patient-defined outcomes. Analyses should distinguish within-person changes from differences between people and assess whether changes are mediated by the processes the theory predicts. Where ethical and feasible, randomized comparison of treatment components can improve the identification of causal mechanisms.
Research programs should publish adverse-event reporting, negative findings, protocol deviations, and subgroup analyses transparently. Subgroup effects require sufficient sample size and, ideally, independent replication. Social and demographic categories should be interpreted in relation to measurable exposure, access, and context, with caution against treating observed health inequities as innate differences.
Finally, evidence synthesis should be cumulative. New trials should be compared with the established randomized evidence, the 2018 psychosocial network meta-analysis De Crescenzo (2018), the 2021 cocaine treatment synthesis Bentzley (2021), and the 2024 ASAM/AAAP guideline American Society of Addiction Medicine & American Academy of Addiction Psychiatry (2024). Such comparison helps identify whether a new result changes practice, refines a population-specific recommendation, or remains an interesting but early signal.
The Artificial Era and Research on Clinical Decision Support
The Artificial Era introduces new methods of information retrieval, risk detection, and longitudinal support for addiction treatment. Automated systems may assist clinicians in organizing toxicology results, identifying missed appointments, presenting evidence summaries, or supporting adherence to an intervention protocol. Such systems should be assessed through their measurable effects on care, including error rates, equity, privacy, retention, clinical outcomes, and user trust.
Clinical decision support involves a particularly important boundary between describing evidence and selecting treatment. The evidence for a behavioral intervention does not, by itself, validate an artificial system that recommends it. Recommendation quality also depends on accurate interpretation of clinical context, current guidelines, contraindications, local availability, and clinician accountability. A generated explanation that looks authoritative can be wrong; reproducible source linkage and systematic error evaluation are therefore central to scientific assessment.
Digital contingency management offers a concrete research domain. The mechanism of reinforcement can be represented by a defined schedule of verified behavior and programmed consequences. Its clinical efficacy remains a question for controlled trials that account for missing data, fraudulent or erroneous verification, socioeconomic access, and the quality of accompanying human care. Technical automation may increase reach, but effects attributed to an artificial component require comparisons that isolate what the component actually changes.
In the theoretical horizon From Homo to Artificial, this constitutes an empirical field of human–artificial coordination in healthcare. Philosophical interpretations of artificial agency, subjecthood, or autonomous reason belong to their own conceptual inquiry. The evidence addressed here concerns observed clinical and organizational outcomes, preserving the distinction between a researchable intervention function and an attribution of inner psychological states.
Conclusion
Stimulant use disorders are disorders of behavior, health, and lived context in which cocaine and methamphetamine exposures interact with reinforcement learning, cue sensitivity, psychiatric vulnerability, physiological risk, and changing social opportunities. Their scientific understanding requires combining biological mechanisms with diagnostic classification, clinical epidemiology, prospective psychological observation, randomized intervention trials, and critical analysis of treatment delivery.
Cocaine and methamphetamine share some reinforcing effects while differing in pharmacological mechanism and temporal profile. Diagnostic evaluation must distinguish use from disorder, acute intoxication from chronic course, withdrawal from independent psychiatric symptoms, and substance-related harm from a complete addiction diagnosis. Psychosis, cardiovascular emergencies, sleep disruption, and polydrug exposure deserve independent clinical attention because their urgency and causal mechanisms differ.
The most robustly supported psychosocial intervention is contingency management, particularly when embedded in comprehensive care with other evidence-based methods. Systematic treatment comparisons indicate the importance of combining reinforcement with community alternatives and skills-based interventions where appropriate. Pharmacological studies have yielded meaningful, selective findings, notably the naltrexone–bupropion trial for methamphetamine use disorder, while absolute response, replication, safety, and generalizability remain fundamental questions.
A complete research perspective considers both the efficacy of treatments and their actual availability. The clinical advantages shown in controlled environments must survive the constraints of financing, staffing, social inequality, comorbidity, and discontinuity of care. Long-term recovery research requires carefully specified measures of substance use, health, psychological functioning, relationships, and quality of life.
Stimulant use disorders thus offer a particularly informative case of how neural pharmacology, learning, social context, and healthcare institutions jointly shape behavioral trajectories. The continuing scientific program is to identify reliable mechanisms, develop better treatments, extend access to effective care, and evaluate recovery over the time scales on which human lives actually unfold.
References
- Acheson, L. S., Williams, B. H., Farrell, M., McKetin, R., Ezard, N., & Siefried, K. J. (2023). Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials. Drug and Alcohol Review, 42(1), 7–19. https://doi.org/10.1111/dar.13511
- American Society of Addiction Medicine & American Academy of Addiction Psychiatry. (2024). The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. Journal of Addiction Medicine, 18(1S Suppl 1), 1–56. https://doi.org/10.1097/ADM.0000000000001299
- Bentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., & Halpern, C. H. (2021). Comparison of treatments for cocaine use disorder among adults: A systematic review and meta-analysis. JAMA Network Open, 4(5), e218049. https://doi.org/10.1001/jamanetworkopen.2021.8049
- Brown, H. D., & DeFulio, A. (2020). Contingency management for the treatment of methamphetamine use disorder: A systematic review. Drug and Alcohol Dependence, 216, 108307. https://doi.org/10.1016/j.drugalcdep.2020.108307
- Centers for Disease Control and Prevention, National Center for Health Statistics. (2026, May 13). U.S. overdose deaths decrease for third consecutive year in 2025. https://www.cdc.gov/nchs/pressroom/releases/20260513.html
- Chan, B., Kondo, K., Freeman, M., Ayers, C., Montgomery, J., & Kansagara, D. (2019). Pharmacotherapy for cocaine use disorder—A systematic review and meta-analysis. Journal of General Internal Medicine, 34(12), 2858–2873. https://doi.org/10.1007/s11606-019-05074-8
- Coffin, P. O., Santos, G.-M., Hern, J., Vittinghoff, E., Walker, J. E., Matheson, T., Santos, D., Colfax, G., & Batki, S. L. (2020). Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: A placebo-controlled randomized clinical trial. JAMA Psychiatry, 77(3), 246–255. https://doi.org/10.1001/jamapsychiatry.2019.3655
- Colfax, G. N., Santos, G.-M., Das, M., Santos, D. M., Matheson, T., Gasper, J., Shoptaw, S., & Vittinghoff, E. (2011). Mirtazapine to reduce methamphetamine use: A randomized controlled trial. Archives of General Psychiatry, 68(11), 1168–1175. https://doi.org/10.1001/archgenpsychiatry.2011.124
- De Crescenzo, F., Ciabattini, M., D'Alò, G. L., De Giorgi, R., Del Giovane, C., Cassar, C., Janiri, L., Clark, N., Ostacher, M. J., & Cipriani, A. (2018). Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. PLOS Medicine, 15(12), e1002715. https://doi.org/10.1371/journal.pmed.1002715
- Kennedy, A. J., Bhatraju, E. P., & Chan, B. (2026). Contingency management for the treatment of stimulant use disorder. JAMA Internal Medicine, 186(7), 892–893. https://doi.org/10.1001/jamainternmed.2026.1163
- Rawson, R. A., McCann, M. J., Flammino, F., Shoptaw, S., Miotto, K., Reiber, C., & Ling, W. (2006). A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction, 101(2), 267–274. https://doi.org/10.1111/j.1360-0443.2006.01312.x
- Substance Abuse and Mental Health Services Administration. (2021). Treatment for stimulant use disorders (Treatment Improvement Protocol Series 33; updated edition; originally published 1999). U.S. Department of Health and Human Services. https://www.ncbi.nlm.nih.gov/books/NBK576541/
- Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., Sparenborg, S., Coffin, P., Schmitz, J., Wiest, K., Bart, G., Sonne, S. C., Wakhlu, S., Rush, A. J., Nunes, E. V., & Shoptaw, S. (2021). Bupropion and naltrexone in methamphetamine use disorder. The New England Journal of Medicine, 384(2), 140–153. https://doi.org/10.1056/NEJMoa2020214
- Vearrier, D., Greenberg, M. I., Miller, S. N., Okaneku, J. T., & Haggerty, D. A. (2012). Methamphetamine: History, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Disease-a-Month, 58(2), 38–89. https://doi.org/10.1016/j.disamonth.2011.09.004
- Volkow, N. D., Wang, G.-J., Fischman, M. W., Foltin, R. W., Fowler, J. S., Abumrad, N. N., Vitkun, S., Logan, J., Gatley, S. J., Pappas, N., Hitzemann, R., & Shea, C. E. (1997). Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature, 386, 827–830. https://doi.org/10.1038/386827a0
- World Health Organization. (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. https://www.who.int/publications/i/item/9789240077263
- World Health Organization. (n.d.). Alcohol, drugs and addictive behaviours: Terminology and diagnostic categories in ICD-11. https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/terminology
Social Environment, Structural Vulnerability, and Recovery Opportunities
The environment of stimulant use includes social ties, employment demands, neighborhood availability, housing stability, stigma, treatment financing, and exposure to violence or instability. These factors affect opportunities for acquisition and use, the costs of seeking care, and the feasibility of changing daily routines. A model focused only on individual impulse control overlooks social contingencies that make certain behaviors easier and alternative reinforcers harder to obtain.
Housing instability and limited transport may interfere with attending frequent appointments or supplying supervised toxicology specimens. Stigma and fear of punitive consequences can reduce disclosure and continuity of care. Differential access to mental healthcare and infectious disease services can compound complications even when underlying levels of exposure are comparable. Treatment trials recruiting from specialized clinics may therefore select individuals with greater practical capacity to participate than some high-risk community populations.
The community reinforcement approach addresses this broader reinforcement environment by increasing access to rewarding substance-free activities and relationships. It represents an attempt to change the structure of everyday consequences rather than relying exclusively on instruction or insight. The evidence for combining it with contingency management was especially favorable in De Crescenzo et al.'s (2018) network meta-analysis De Crescenzo (2018), subject to limitations of the underlying comparisons.
Culturally responsive research should specify how interventions were adapted and whether the adaptations preserve the active ingredients of the treatment. Assumptions that the same incentives, monitoring arrangements, and clinic schedules will be equally acceptable to different groups are empirical hypotheses, not established facts. Stimulant-use treatment is therefore simultaneously an individual clinical problem and an implementation problem organized by institutions and communities.